Clinical trials: Diarrhea
Gastrointestinal Health
Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions
US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms.
- Trial name
- NCT05465629
- Testing
- VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Clostridium Difficile Infection, Clostridium Difficile Diarrhea
Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity
This Phase I, randomized, placebo-controlled, double-blinded, dose ranging study to assess the safety, tolerability, and immunogenicity of 2 dose levels of C. difficile vaccine.
- Trial name
- NCT00772954
- Testing
- Vaccine diluent buffer, Clostridium difficile toxoid vaccine (50 μg), Clostridium difficile toxoid vaccine (100 μg)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diarrhoea
Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea
Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several studies demonstrating their efficacy, the investigators are conducting this study to look into the efficacy and safety of IQP-MM-101 in…
- Trial name
- NCT01969214
- Testing
- IQP-MM-101
- Where
- Germany
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Clostridioides Difficile Infection
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
- Trial name
- Ri-CoDIFy 3 (NCT04802837)
- Testing
- Ridinilazole, Vancomycin
- Where
- 18 sites in United States
- Volunteers
- 2 people
- Sponsor
- Summit Therapeutics
Diarrhea, Infantile
Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea
This is a prospective, open-label, multicenter, single-arm study evaluating the efficacy and safety of Racecadotril the treatment of children aged 3 to 60 months suffering from acute diarrhea
- Trial name
- NCT03473561
- Testing
- Racecadotril plus ORS
- Where
- 2 sites in Taiwan
- Volunteers
- 31 people
- Sponsor
- Abbott
Clostridium Infections, Diarrhea
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT00468728
- Testing
- PAR-101/OPT-80, Vancomycin
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 535 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diarrhea Caused by Drug (Disorder)
A Study of FT1 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of FT1 in participants aged 18 to 45 years. The main questions it aims to answer are: Is FT1 safe in healthy adults? Researchers will compare FT1 to a placebo (a…
- Trial name
- NCT06610487
- Testing
- FT1
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Irritable Bowel Syndrome with Diarrhea
Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The aim of this study is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.
- Trial name
- NCT04492787
- Testing
- Changkang Granule
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Diarrhea-predominant Irritable Bowel Syndrome
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01870895
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
Healthy Term Infants
The Combiotic-Study
The primary objective of this study is to demonstrate that a synbiotic formula, fed for the duration of the first year of life (infant and follow-on formula) reduces the incidence rate of episodes of infectious diarrhea in…
- Trial name
- GOLFIII (NCT02221687)
- Testing
- Synbiotic formula, Control formula
- Where
- 25 sites in France
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- HiPP GmbH & Co. Vertrieb KG
Cryptosporidiosis, HIV Infections
Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)
To evaluate the safety and efficacy of diclazuril capsules compared with placebo capsules as treatment of cryptosporidial related diarrhea in AIDS patients.
- Trial name
- NCT00002027
- Testing
- Diclazuril
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Janssen, LP
Neoplasm Metastasis, Colorectal Neoplasms
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences.
- Trial name
- NCT00037180
- Testing
- Celecoxib, Irinotecan, 5-fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 212 people
- Sponsor
- Pfizer
Irritable Bowel Syndrome With Diarrhea
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome
Several probiotic strains have shown beneficial outcomes in IBS patients, particularly among the Lactobacillus and Bifidobacterium genera, Lactobacillus plantarum (recently reclassified as Lactiplantibacillus plantarum) is a…
- Trial name
- NCT04950296
- Testing
- Group I: L. plantarum UALp-05TM,, Group II: L. plantarum UALp-05TM,, Microcrystalline cellulose
- Where
- 12 sites in India
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Renal Cell Carcinoma, Melanoma
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4…
- Conditions
- Renal Cell Carcinoma, Melanoma, Lung Cancer
- Trial name
- NCT02763761
- Testing
- Infliximab + Prednisone, Methylprednisolone + Prednisone
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Clostridium Enterocolitis, Diarrhea
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
Approximately 520 patients will be entered into this study taking place throughout Australia and Europe. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C.
- Trial name
- NCT00196794
- Testing
- Tolevamer potassium-sodium (GT267-004)
- Where
- 138 sites in Australia, Austria and 12 more
- Volunteers
- 520 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Diarrhea
Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea
The purpose of this study is to determine whether a medical nutrition product, PTM202, along with standard of care, enhances recovery and reduces diarrhea morbidity in young children
- Trial name
- NCT01814202
- Testing
- PTM202
- Where
- Bangladesh
- Volunteers
- 68 people
- Sponsor
- PanTheryx, Inc.